Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience

Abstract

AGCC patients who were treated with FOLFOX chemotherapy in the adjuvant setting or FOLFOX/FOLFIRI in the metastatic setting experienced prolonged PFS, DFS, and OS. Five patients with peritoneal-limited disease treated with CRS plus HIPEC have not yet reached median PFS or OS. While small sample size, patient selection, and retrospective nature limit the generalizability of findings from our analysis, the efficacy signals we observed suggest prospective evaluation with chemotherapy and CRS plus HIPEC is warranted in AGCC patients.

Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry

“…It is likely that this finding is the result of referral bias, as higher rates of metastatic disease were reported by tertiary centres, with lower rates reported by district general hospitals and national registry studies ( 52 ). The most common sites of metastases were the peritoneum, liver, small bowel, and ovaries ( 11 , 28 , 37 , 49 , 52 , 89 , 90 ).…”

“…The most common palliative chemotherapy regimens were similar to those used in colonic adenocarcinoma, either 5-FU-based or a combination of capecitabine and oxaliplatin ( 7 , 28 , 37 , 52 , 54 ). More rarely, authors used a small-cell lung cancer-based regimen such as carboplatin and etoposide, a NEN regimen such as streptozocin and 5-FU, or an ovarian cancer regimen such as carboplatin and docetaxel ( 58 ).…”

“…There were variable results among smaller studies. In one case series of high-grade GCA, patients treated with palliative folinic acid, fluorouracil, and oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) had a progression-free survival (PFS) of 21.5 months and median OS of 32.9 months ( 37 ), yet in a retrospective analysis of 24 patients, the PFS was only 5.3 months ( 52 ).…”

“…The use of CRS-HIPEC in patients with peritoneal spread was investigated in multiple retrospective studies ( 10 , 27 , 29 – 31 , 36 , 37 , 47 , 50 , 51 , 57 , 60 , 65 , 74 ). Most showed a median OS between 17 and 45 months ( 29 , 47 , 50 , 57 , 65 , 74 ).…”

“…In studies classifying GCA as local, regional, or metastatic disease, 51%-64% of cases were described as local (3,16,17,26). While metastases were found in only a relatively small proportion of cases in the registry studies (7%-18.7%) (3, 11, 12, 16-20, 23, 26), stage IV disease was more common in retrospective studies and case series (7,37,39,44,49,52,58,73). It is likely that this finding is the result of referral bias, as higher rates of metastatic disease were reported by tertiary centres, with lower rates reported by district general hospitals and national registry studies (52).…”